A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs TDENV PIV (Primary) ; AS03B
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- 12 Oct 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
- 12 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 15 Jun 2018.
- 18 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.